Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30011163HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30082536HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30022115HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30017701HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30017503HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS20029992HPVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS20047321HPVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS44028790HTLV-1ENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TCGA Plot Options
Drug Information
GenePIK3CD
DrugBank IDDB14989
Drug NameUmbralisib
Target IDBE0002406
UniProt IDO00329
Regulation Typeinhibitor
PubMed IDs29475723; 30936084; 31558467; 32634240
CitationsBurris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20.@@Authors unspecified: Umbralisib: Treatment for a Rare Lymphoma? Cancer Discov. 2019 Jun;9(6):OF5. doi: 10.1158/2159-8290.CD-NB2019-045. Epub 2019 Apr 1.@@Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S: Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 Nov 21;134(21):1811-1820. doi: 10.1182/blood.2019002118.@@Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, Fonseca R, Jiang K, Miskin HP, Maryanski D, Monastyrskyi A, Duckett DR, Roush WR, Cleveland JL, Sahakian E, Pinilla-Ibarz J: The dual PI3Kdelta/CK1epsilon inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul 14;4(13):3072-3084. doi: 10.1182/bloodadvances.2020001800.
GroupsApproved; Investigational; Withdrawn
Direct Classification
SMILESCC(C)OC1=C(F)C=C(C=C1)C1=NN([C@@H](C)C2=C(C3=CC=CC(F)=C3)C(=O)C3=CC(F)=CC=C3O2)C2=C1C(N)=NC=N2
Pathways
PharmGKB
ChEMBLCHEMBL3948730